FindMyKOL
Clinical trialNCT00743509CompletedPhase 2Interventional

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

NCT00743509 is a phase 2 interventional trial sponsored by University of Michigan Rogel Cancer Center. As of 21 Nov 2026, it is completed. It studies Cyclophosphamide and Sirolimus in Osteosarcoma. The registry lists an enrollment of 49 participants at 1 site in 1 country. The registry lists a start date of 31 Aug 2008 and a primary completion date of 30 Apr 2010. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00743509
FieldValue
Registry IDNCT00743509
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorUniversity of Michigan Rogel Cancer Center
Enrollment49
Registered sites1
Countries1
ConditionsOsteosarcoma
DrugsCyclophosphamide and Sirolimus
Start31 Aug 2008
Primary completion30 Apr 2010
Study completion30 Sept 2012
Last update posted28 Sept 2015

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this Phase II study will assess the effectiveness of the combination of oral cyclophosphamide and sirolimus in sarcoma patients with relapsed or widespread disease who cannot be cured by surgery, radiation or conventional chemotherapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Michigan, United States1 site
  • University of Michigan

    Ann Arbor

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 1 siteMI1New YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide and Sirolimus
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00743509

Each answer restates registry values shown on this page.

What is NCT00743509?

NCT00743509 is a phase 2 interventional trial sponsored by University of Michigan Rogel Cancer Center. It studies Cyclophosphamide and Sirolimus in Osteosarcoma.

Who leads NCT00743509?

The registry names Scott Schuetze, MD, PhD (principal investigator, University of Michigan Rogel Cancer Center) as the overall official.

Where does NCT00743509 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00743509 study?

The registered drug and biological interventions are Cyclophosphamide and Sirolimus.

When did NCT00743509 end?

The registry lists a primary completion date of 30 Apr 2010 and a study completion date of 30 Sept 2012. The sponsor last updated the record on 28 Sept 2015.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.